Interesting Study on E2 and Testosterone-induced Visceral Fat Loss

NbleSavage

Veteran
SI Founding Member
Joined
Apr 29, 2012
Messages
11,995
Reaction score
11,983
Points
383
http://jap.physiology.org/content/121/3/792.abstract?cpetoc

(Bolding Mine)

Abstract

The influence of the aromatase enzyme on the chronic fat-sparing effects of testosterone requires further elucidation. Our purpose was to determine whether chronic anastrozole (AN, an aromatase inhibitor) treatment alters testosterone-mediated lipolytic/lipogenic gene expression in visceral fat. Ten-month-old Fischer 344 rats (n = 6/group) were subjected to sham surgery (SHAM), orchiectomy (ORX), ORX + treatment with testosterone enanthate (TEST, 7.0 mg/wk), or ORX + TEST + AN (0.5 mg/day), with drug treatment beginning 14 days postsurgery. At day 42, ORX animals exhibited nearly undetectable serum testosterone and 29% higher retroperitoneal fat mass than SHAM animals (P < 0.001). TEST produced a ∼380-415% higher serum testosterone than SHAM (P < 0.001) and completely prevented ORX-induced visceral fat gain (P < 0.001). Retroperitoneal fat was 21% and 16% lower in ORX + TEST than SHAM (P < 0.001) and ORX + TEST + AN (P = 0.007) animals, while serum estradiol (E2) was 62% (P = 0.024) and 87% (P = 0.010) higher, respectively. ORX stimulated lipogenic-related gene expression in visceral fat, demonstrated by ∼84–154% higher sterol regulatory element-binding protein-1 (SREBP-1, P = 0.023), fatty acid synthase (P = 0.01), and LPL (P < 0.001) mRNA than SHAM animals, effects that were completely prevented in ORX + TEST animals (P < 0.01 vs. ORX for all). Fatty acid synthase (P = 0.061, trend) and LPL (P = 0.043) mRNA levels were lower in ORX + TEST + AN than ORX animals and not different from SHAM animals but remained higher than in ORX + TEST animals (P < 0.05). In contrast, the ORX-induced elevation in SREBP-1 mRNA was not prevented by TEST + AN, with SREBP-1 expression remaining ∼117–171% higher than in SHAM and ORX + TEST animals (P < 0.01). Across groups, visceral fat mass and lipogenic-related gene expression were negatively associated with serum testosterone, but not E2. Aromatase inhibition constrains testosterone-induced visceral fat loss and the downregulation of key lipogenic genes at the mRNA level, indicating that E2 influences the visceral fat-sparing effects of testosterone.
 

stonetag

Elite
Joined
Dec 2, 2013
Messages
7,405
Reaction score
6,283
Points
283
Felt like I was back in biology class reading that Savage!! Thanks for the flashback anyway...lol
 

NbleSavage

Veteran
SI Founding Member
Joined
Apr 29, 2012
Messages
11,995
Reaction score
11,983
Points
383
Felt like I was back in biology class reading that Savage!! Thanks for the flashback anyway...lol

How I interpreted it: "Eh, Mate - maybe don't crush yer E2 and ye'll lose more fat, yea?"

Or more to the point: being in the high end of the 'Normal' E2 range may be the optimal place to be.
 
Top